CellCarta Acquires Biogazelle

Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)

October 4, 2022

Biotechnology

Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

CellCarta Acquires Reveal Biosciences

May 11, 2021

Healthcare Services

CellCarta has acquired Reveal Biosciences, a San Diego–based computational pathology company specializing in AI-driven quantitative pathology and digital image analysis. The acquisition adds Reveal's imageDx platform and AI-based pathology capabilities to CellCarta's histological biomarker and precision medicine services, broadening its AI-enabled multi-omic analysis offerings for biopharmaceutical research and clinical trials.

Lonza AG Acquires PharmaCell BV

June 1, 2017

Biotechnology

Lonza AG has completed the acquisition of PharmaCell BV, a leading European contract manufacturer of cell and gene therapies with facilities in Maastricht and Sittard-Geleen. The deal expands Lonza's autologous cell-therapy manufacturing capabilities in Europe and integrates PharmaCell's GMP production capacity and experienced team into Lonza's global CDMO network.

BioAgilytix Acquires Cambridge Biomedical

November 4, 2019

Healthcare Services

BioAgilytix, a GHO Capital portfolio company, has acquired Cambridge Biomedical, a Cambridge, Massachusetts–based clinical research organisation specializing in large-molecule bioanalysis. The deal expands BioAgilytix's laboratory capacity and capabilities (including CLIA/CAP/GLP capabilities and PCR/molecular suites), broadens its geographic footprint into the Boston/Cambridge biotech cluster, and strengthens its cell- and gene-therapy bioanalytical offerings.

Discovery Life Sciences Acquires AllCells

July 12, 2022

Biotechnology

Discovery Life Sciences has acquired AllCells to create an integrated, end-to-end provider of clinical-grade and RUO primary cell products and analytic services for the cell and gene therapy (CGT) continuum. The combined business — operating as AllCells, a Discovery Life Sciences Company and led by AllCells CEO Danny Zheng — aims to expand GMP-compliant starting materials, donor programs and multi‑omic characterization to accelerate CGT discovery through commercialization.